T he gene-encoded synthesis and Darwinian selection of sequence-defined biopolymers are fundamental features of all known forms of life. These processes have been harnessed in the laboratory to evolve RNA 1-3 , DNA 4-6 and polypeptides 7-10 with a variety of binding and catalytic properties through iterated cycles of biopolymer translation, selection, replication, and mutation. The speed and effectiveness of the evolutionary process have inspired efforts to apply these principles to the much larger chemical space of synthetic polymers 11 . To date, however, the evolution of sequencedefined non-natural polymers in the laboratory has been limited to analogues of nucleic acids 12-15 and polypeptides 16 that can be synthesized by polymerases and ribosomes. Polymerases and ribosomes impose structural requirements on the building blocks that can be polymerized and thereby limit the diversity of synthetic polymers that are accessible to directed evolution. For example, polymerases use only mononucleotides as substrates, which precludes the ability to encode a diverse set of codons and side chains. Known classes of polymerase-synthesized functional non-natural nucleic acid polymers, including those derived from non-natural sugar backbones 17-20 , the uniform installation of hydrophobic 21-28 or positively charged 29-35 side chains on nucleobases, or the introduction of novel nucleobases to the four canonical possibilities 36-38 , therefore have chemical diversities that are only modestly expanded beyond those of natural DNA and RNA, and fall short of the much more diverse chemical functionality present in proteins.
T he gene-encoded synthesis and Darwinian selection of sequence-defined biopolymers are fundamental features of all known forms of life. These processes have been harnessed in the laboratory to evolve RNA 1-3 , DNA 4-6 and polypeptides 7-10 with a variety of binding and catalytic properties through iterated cycles of biopolymer translation, selection, replication, and mutation. The speed and effectiveness of the evolutionary process have inspired efforts to apply these principles to the much larger chemical space of synthetic polymers 11 . To date, however, the evolution of sequencedefined non-natural polymers in the laboratory has been limited to analogues of nucleic acids [12] [13] [14] [15] and polypeptides 16 that can be synthesized by polymerases and ribosomes. Polymerases and ribosomes impose structural requirements on the building blocks that can be polymerized and thereby limit the diversity of synthetic polymers that are accessible to directed evolution. For example, polymerases use only mononucleotides as substrates, which precludes the ability to encode a diverse set of codons and side chains. Known classes of polymerase-synthesized functional non-natural nucleic acid polymers, including those derived from non-natural sugar backbones [17] [18] [19] [20] , the uniform installation of hydrophobic [21] [22] [23] [24] [25] [26] [27] [28] or positively charged [29] [30] [31] [32] [33] [34] [35] side chains on nucleobases, or the introduction of novel nucleobases to the four canonical possibilities [36] [37] [38] , therefore have chemical diversities that are only modestly expanded beyond those of natural DNA and RNA, and fall short of the much more diverse chemical functionality present in proteins.
Previously, we developed an in vitro system that uses DNA ligase to translate DNA sequences into sequence-defined highly functionalized nucleic acid polymers (HFNAPs) that contain a wide range of side chains chosen by the researcher 39 . In our original report, we showed that DNA sequences can be translated into HFNAPs using DNA ligase to catalyse the polymerization of up to 50 consecutive short chemically functionalized oligonucleotide building blocks along a DNA template 39 (Fig. 1a ). We discovered that T4 DNA ligase accepts trinucleotide building blocks with a wide range of side chains on the 5′ nucleobase, including side chains at the C5 position of pyrimidine nucleobases that are both synthetically accessible and unlikely to disrupt Watson-Crick base pairing 39 . This artificial translation system allows researchers, in principle, to mimic and even expand the chemical repertoire of protein building blocks in an evolvable synthetic polymer system. The broad chemical scope of HFNAPs gives them the potential to adopt unique folding and functional properties distinct from those of known natural or non-natural nucleic acid polymers. However, the original HFNAP system proved difficult to support the evolution of functional polymers, probably because of the limited diversity provided by its eight-codon genetic code and the long, flexible linkers present in the building blocks. In this study, we designed a new HFNAP 'genetic code' , translation and in vitro selection system that overcomes these challenges, and then applied the resulting HFNAP evolution system to generate sequence-defined synthetic polymers that bind two protein targets of biomedical interest.
Results
Our new genetic code was designed to offer a high degree of both codon and side-chain diversity to the evolving polymers ( Fig. 1b) . We included the maximum number of different trinucleotides that contained 5′ pyrimidine (all 32 possible YNN combinations, where Y = C or T and N = A, C, G or T) as codons. The corresponding 32 building blocks were each linked to one of eight side chains (four codons per side chain), which include hydrophobic, aliphatic, aromatic, halogenated, polar and charged groups, several of which are not found among proteinogenic amino acid side chains. The linkers between side chains and nucleobases were redesigned compared with our original genetic code to have limited conformational flexibility to increase the likelihood that the polymer backbone, nucleobases and side chains would cooperatively adopt defined folded structures. We assigned each side-chain to a set of four codons that collectively contained the same balance of A/T versus C/G bases following the side-chain-functionalized 5′ -pyrimidine base.
Evolution of sequence-defined highly functionalized nucleic acid polymers
Zhen Chen 1,2,3 , Phillip A. Lichtor 1,2,3 , Adrian P. Berliner 1,2,3 , Jonathan C. Chen 1,2,3 and David R. Liu 1,2,3 * The evolution of sequence-defined synthetic polymers made of building blocks beyond those compatible with polymerase enzymes or the ribosome has the potential to generate new classes of receptors, catalysts and materials. Here we describe a ligase-mediated DNA-templated polymerization and in vitro selection system to evolve highly functionalized nucleic acid polymers (HFNAPs) made from 32 building blocks that contain eight chemically diverse side chains on a DNA backbone. Through iterated cycles of polymer translation, selection and reverse translation, we discovered HFNAPs that bind proprotein convertase subtilisin/kexin type 9 (PCSK9) and interleukin-6, two protein targets implicated in human diseases. Mutation and reselection of an active PCSK9-binding polymer yielded evolved polymers with high affinity (K D = 3 nM). This evolved polymer potently inhibited the binding between PCSK9 and the low-density lipoprotein receptor. Structure-activity relationship studies revealed that specific side chains at defined positions in the polymers are required for binding to their respective targets. Our findings expand the chemical space of evolvable polymers to include densely functionalized nucleic acids with diverse, researcher-defined chemical repertoires.
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We improved the DNA-templated polymerization (artificial 'translation') reactions by screening ligase enzymes and adjusting polymerization conditions. We found that subjecting translation reactions to a slow (-0.01 °C s -1 ) temperature ramp to 4 °C before initiating the ligation with T3 DNA ligase substantially improved the yields of full-length HFNAPs from libraries of DNA templates that contained random coding regions of 45 nucleotides, which encoded the incorporation of 15 consecutive side-chain-functionalized trinucleotide building blocks of mixed sequence ( Fig. 1c and Supplementary Fig. 1 ). To test the ability of translated polymers to be 'reverse translated' back into DNA, and thereby enable iterated cycles of translation, selection, reverse translation and PCR amplification, we performed polymerization on four templates that each encoded the incorporation of eight different building blocks and collectively covered all 32 building blocks, and then subjected the resulting HFNAP products, separated from the template DNA, to reverse translation in a PCR reaction using Q5 DNA polymerase 39 (Fig. 1d ). One of the PCR primers binds a 3′ overhang ( Fig. 1d , green) present in the HFNAP products but absent in template DNA, thereby precluding the amplification of any contaminating template DNA. DNA sequencing of the resulting PCR products showed that the original sequence information in the templates was recovered faithfully (Fig. 1d ), which indicates that both the translation from DNA to HFNAPs and the reverse translation from HFNAPs to their 
encoding DNA occur with high sequence fidelity using this set of building blocks. These observations are qualitatively consistent with results from other research that reported fidelities that ranged from 95.1% to 98.4% per codon for the ligase-mediated DNA-templated polymerization of functionalized pentanucleotides 40 . Perfect fidelity is not expected for a ligase-mediated polymerization, which lacks proofreading mechanisms, but we reasoned that the level of fidelity in our system may be sufficient to support an iterated selection for functional polymers, consistent with our previous mock-selection results 39 . Modest levels of mutations may also confer a benefit to the selection, as already reported for selections of aptamers that contain novel nucleobases 37 .
Encouraged by these developments, we generated a library of HFNAPs that each contained 15 consecutive building blocks drawn from the set of 32 (theoretical polymer library space: 3 × 10 22 ; average HFNAP molecular weight: 28 kDa) and subjected the resulting library (starting quantity: 3 × 10 12 molecules) to iterated rounds of in vitro selection for binding to the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein, a target implicated in low-density lipoprotein metabolism and cardiovascular disease [41] [42] [43] (Fig. 2a ). The HFNAP library was incubated with PCSK9 protein immobilized on agarose beads. After washing the beads with buffer, the bound HFNAPs were eluted by boiling the beads in buffer that contained detergent. The surviving HFNAPs were reverse translated in a PCR reaction using Q5 DNA polymerase, and the resulting double-stranded DNAs were purified by polyacrylamide gel electrophoresis (PAGE). The non-template strands were removed by alkaline denaturation, and the streptavidin-bound template strands were translated back into HFNAPs by the ligase-catalysed DNAtemplated polymerization for the next round of PCSK9-binding selection. The ability of HFNAPs to be reverse translated directly by a DNA polymerase, though not an absolute requirement for iterated selection, as demonstrated by the use of display methods to evolve nucleic acids 17, 44 , provides a practical and high-fidelity way to complete a selection cycle.
As the iterated rounds of selection progressed, the fraction of HFNAPs that was retained on the PCSK9-linked beads generally increased, consistent with enrichment of PCSK9-binding polymers, even though we steadily elevated the selection stringency by decreasing the amount of PCSK9 protein ( Fig. 2b) . At the eighth round of selection, the polymer population was retained by PCSK9 protein-conjugated agarose beads with an efficiency of approximately 10%. In contrast, less than 0.1% of the same polymer population was retained on agarose beads not conjugated to any protein ( Fig. 2b) , which suggests that the ability of the selected polymers to bind PCSK9-linked beads arose from their ability to bind PCSK9, rather than agarose beads.
Results from high-throughput DNA sequencing after nine rounds of selection indicated that the HFNAP pool had strongly converged to just seven sequence families that contained conserved subsequences suggestive of common binding motifs ( Supplementary  Fig. 2 ). Sequences within the same family were probably descendants of a single parental polymer derived through mutations that accumulated through the selection process, as evidenced by high levels of sequence similarity. We individually synthesized the seven most-highly enriched HFNAPs by ligase-mediated DNA-templated polymerization and tested their retention on immobilized PCSK9 or immobilized thrombin, an unrelated protein. Five of the seven tested polymers exhibited substantial apparent binding activity to immobilized PCSK9 beyond any apparent binding to immobilized thrombin. We also assayed unfunctionalized DNA sequences (lacking any side-chains) that corresponded to these seven HFNAPs and observed no evident PCSK9-binding activity ( Supplementary  Fig. 2 ). Together, these results suggest that the HFNAP populations emerging from nine rounds of in vitro selection converged on a small number of polymer families that bind immobilized PCSK9 in a manner dependent on the polymers' side chains.
We characterized PCSK9-A5 ( Fig. 2c ), the polymer with the highest apparent PCSK9-binding activity, in depth. We synthesized biotinylated PCSK9-A5 by templated translation and confirmed its binding affinity for PCSK9 (dissociation constant K D = 98 nM) by surface plasmon resonance (SPR) (Fig. 2d ). To probe the role of the side-chain functional groups, we synthesized side-chain mutants of PCSK9-A5 in which all instances of each building block were replaced by the corresponding trinucleotide that either lacked any side chain or contained a linker but lacked the side chain's functional group ( Supplementary Fig. 3 ). The removal of a single phenol side chain in codon 9 or a single cyclopentyl side chain in codon 14 completely abolished the binding between PCSK9-A5 and its target ( Fig. 2c ,e, dark red). Furthermore, the removal of the isopentyl side chain at codon 13 resulted in an approximately twofold reduction in affinity ( Fig. 2c ,e, light red). The individual removal of other side chains had less significant effects on binding affinity.
Given the vast sequence space of the HFNAP library (3 × 10 22 possible polymers), evolution would probably generate polymer variants with improved activity over those polymers present in the initial population of 3 × 10 12 HFNAP molecules. To evolve the PCSK9-A5 polymer into variants with improved PCSK9 affinity, we synthesized a library of mutated PCSK9-A5 templates that contained 79% identity and 21% diversity (79:21 at the pyrimidineonly first position and 79:7:7:7 at the second and third positions of each codon) for each nucleotide in the variable region ( Fig. 3a) . We subjected the resulting mutated PCSK9-A5 library to six additional iterated cycles of translation and selection for PCSK9 binding ( Supplementary Fig. 4 ). After just one round of enrichment at a stringency level comparable to that of the last round of our initial selection, the mutated PCSK9-A5 library exhibited a bulk affinity for PCSK9-conjugated beads (Fig. 3b ). High-throughput DNA sequencing revealed that the mutant population after a second round of translation and selection began to converge towards the sequence of PCSK9-A5 at many positions (Fig. 3a) . In subsequent rounds, we reduced the amount of immobilized PCSK9 to increase the selection stringency further. Four additional rounds of translation and selection resulted in steadily improved retention of the polymer population on immobilized PCSK9 (Fig. 3b ).
High-throughput sequencing revealed new consensus codons at four out of 15 positions within the population of evolved polymers ( Fig. 3a ). Among these four positions, codons 6, 10 and 12 evolved a different side chain compared with that of PCSK9-A5, whereas codon 9 evolved a different codon (TGT instead of TTT) that encoded the same phenol side chain at this position. In addition, five other codons converged to the original sequence in PCSK9-A5, and six other codon positions, mostly near the 5′ end, retained the sequence heterogeneity introduced during mutation, which suggests that these positions do not strongly contribute to the binding activity (Fig. 3a) . The three side-chain functional groups that were shown to be crucial to the PCSK9-binding activity of PCSK9-A5 were all maintained in the consensus sequence of the evolved polymer population.
We synthesized a biotinylated, truncated HFNAP (designated PCSK9-Evo5 (Fig. 3c) ) that retained only the evolved consensus sequence and the 3′ constant region, and measured its affinity for PCSK9 to be K D = 3.0 nM ( Fig. 3d and Supplementary Fig. 5 ), which represents a 33-fold increase over that of PCSK9-A5. In contrast, a similarly truncated version of PCSK9-A5 (designated PCSK9-A5Trunc) did not substantially improve affinity (K D = 68 nM) over that of full-length PCSK9-A5 (K D = 98 nM) ( Supplementary Fig. 6 ). Additional truncation of PCSK9-Evo5 from the 3′ end resulted in a complete loss of affinity ( Supplementary Fig. 6 ). Similar to the structure-activity relationships observed for PCSK9-A5, the removal of a single phenol or cyclopentyl side chain from PCSK9-Evo5 abolished Nature Chemistry its affinity to the PCSK9 protein (Fig. 3d) , and the removal of the isopentyl side chain severely impaired target binding (the binding interaction approximately fits a two-state reaction kinetic model with K D ≈ 420 nM ( Fig. 3d and Supplementary Fig. 5) ). The individual removal of other side chains had less significant effects on binding affinity; indeed, an HFNAP that contained only three side chains (phenol at position 9, isopentyl at position 21 and cyclopentyl at position 24) and retained the rest of the Evo5 sequence as unfunctionalized DNA maintains strong binding to PCSK9 (K D = 3.7 nM ( Fig. 3d and Supplementary Fig. 5) ). Together, these results establish the evolution (iterated selection with intervening mutation and replication) of a sequence-defined synthetic polymer with improved target affinity.
To gain further insight into the secondary structures of PCSK9binding HFNAPs and the affinity improvement of PCSK9-Evo5 over PCSK9-A5, we subjected the DNA sequences of PCSK9-Evo5 and PCSK9-A5Trunc to secondary structure prediction using mFold 45 . The 3′ region, conserved between PCSK9-A5Trunc and PCSK9-Evo5, was predicted to form a stem-loop structure that contained a bulge. The 5′ region, which includes all the consensus mutations that lead to PCSK9-Evo5, contained significantly less (in the case of PCSK9-A5Trunc) or no (in the case of PCSK9-Evo5) predicted secondary structure based on Watson-Crick base pairing ( Supplementary Fig. 7) . Consistent with the observed side-chain structure-activity relationships shown in Fig. 3d , these calculations further suggest the crucial contributions of side chains, which are not captured in the secondary structure model, to HFNAP folding and target-binding activity.
To characterize PCSK9-Evo5 further, we executed a multimilligram-scale total synthesis of a variant of PCSK9-Evo5 (PCSK9-Evo5-syn), which has an additional 3′ inverted dT base for exonuclease resistance 46 b, PCSK9-binding selection progress. The HFNAP pool's bulk affinity to PCSK9-coated beads was assessed by quantifying the amount of HFNAPs in the flow-through versus the elution at each round of selection by qPCR. Higher values in the graph indicate higher ratios of polymers that bound to immobilized PCSK9 and were eluted relative to the polymers that flowed through the immobilized PCSK9. C t , threshold cycle. c, Sequence and side-chain structure of selected polymer PCSK9-A5. The side chains essential for the binding activity are boxed. d, SPR sensogram that characterizes the binding kinetics between surface-immobilized PCSK9-A5 polymer and the target PCSK9 protein. The concentrations of injected PCSK9 were 10, 30, 100 and 300 nM. The observed sensogram is shown in red and the fitted curve with the kinetic parameters listed is shown in black. e, Kinetic parameters for the binding of PCSK9-A5 or its side-chain-deficient variants to PCSK9 protein, as measured by SPR. For the variants 'TTT Δ side chain', 'TTT linker only' and 'CTT Δ side chain', no SPR signal was observed at the highest analyte concentration tested (300 nM PCSK9). RU, response unit.
on solid support ( Supplementary Fig. 8 ). We planned to install all side-chain-functionalized building blocks entirely through corresponding side-chain-functionalized phosphoramidite reagents, with the nucleophilic functional groups protected with base-labile protecting groups that would be removed under standard oligonucleotide deprotection conditions. Although most of the sidechain-functionalized nucleoside phosphoramidites were readily synthesized (Supplementary Methods), the imidazole-bearing thymidine reagent proved difficult to prepare. We therefore synthesized PCSK9-Evo5-syn on solid phase with an activated ester (NHS-carboxy-dT) in place of the imidazole-functionalized thymidine, and coupled histamine to that position in the bead-bound polymer chain to install the imidazole side chain before global deprotection and cleavage from the solid support with ammonium hydroxide ( Supplementary Fig. 8 ). The identity of PCSK9-Evo5-syn (approximately 2 mg from a 1 μ mol solid-phase synthesis, ~13% overall yield) was confirmed by high-resolution mass spectrometry ( Supplementary Fig. 9 ). High-affinity binding (K D = 6.8 nM) between totally synthetic PCSK9-Evo5-syn and biotinylated Avitagged PCSK9 was confirmed by SPR ( Fig. 3e ). In addition, the binding of Alexa Fluor 647-labelled Evo5 at low nanomolar concentrations to PCSK9 was confirmed in an electrophoretic mobility shift assay ( Supplementary Fig. 10 ). PCSK9 regulates cholesterol metabolism by binding the lowdensity lipoprotein receptor (LDLR) and promoting the lysosomal degradation of LDLR (ref. 42 ). We tested the ability of PCSK9-Evo5syn to disrupt PCSK9-LDLR binding in an SPR assay. PCSK9-Evo5-syn dose-dependently reduced the binding of PCSK9 to surface-immobilized LDLR ( Fig. 3f and Supplementary Fig. 11 ). The potency of PCSK9-Evo5-syn inhibition of PCSK9-LDLR binding (IC 50 = ~9 nM) was similar to that of a known PCSK9neutralizing monoclonal antibody ( Fig. 3f and Supplementary  Fig. 11 ). In contrast, unfunctionalized DNA of the same sequence as PCSK9-Evo5-syn produced no inhibitory effect ( Fig. 3f and Supplementary Fig. 11 ), consistent with the necessity of the sidechains implicated in PCSK9 binding (Fig. 2c-e and Fig. 3c,d) . We also tested the affinity of surface-immobilized PCSK9-Evo5 to different PCSK9 protein constructs and found that a truncated PCSK9 variant that lacked the prodomain exhibited no apparent binding to PCSK9-Evo5 ( Supplementary Fig. 12 ), which implicates the PCSK9 prodomain, known to be involved in a secondary binding interface between PCSK9 and LDLR (ref. 47 ), in mediating the interaction of PCSK9 with PCSK9-Evo5.
To test the generality of our polymer-evolution system and to investigate the potential of this new class of polymers to generate receptors to different proteins, we performed a separate selection Supplementary Fig. 11 .
for HFNAPs that bind a protein unrelated to PCSK9. We chose human interleukin-6 (IL-6), a key cytokine involved in inflammation and the target of many drugs and drug candidates 48 , including modified DNA aptamers 24, 25 . After seven iterated cycles of translation, selection for binding to immobilized IL-6 protein, reverse translation and amplification, the most abundant sequence accounted for 3.6% of the population (Fig. 4a) . The top seven HFNAPs were synthesized individually and assayed for binding to immobilized IL-6. Based on its high apparent binding activity to immobilized IL-6, but not to immobilized PCSK9 (Fig. 4a) , HFNAP IL6-A7 (Fig. 4b) was chosen for further characterization. Binding of biotinylated IL6-A7 to the target IL-6 protein was confirmed by SPR. Although the binding kinetics of IL6-A7 to IL-6 protein did not conform to a classical one-to-one binding model, a phenomenon often observed in aptamer-protein binding 18, 24 , fitting to a heterogeneous ligand model resulted in apparent affinities of K D = 12 nM for the major component and K D = 22 nM for the minor component (Fig. 4c) .
The binding kinetics and affinity of IL6-A7 to E. coli-expressed IL-6 (used in the selection) and to human HEK293 cell-expressed IL-6 protein were comparable ( Supplementary Fig. 13 ). Next, we measured by SPR the IL-6 affinity of IL6-A7 side-chain mutants in which all the instances of a trimer building block were replaced by the corresponding trinucleotide that lacked any side chain. The mutants without the isopentyl side chain in either codon 14 or codon 15 exhibited severely impaired binding ( Supplementary  Fig. 13 ), which implicates these two side chains as key determinants of the IL-6 binding activity in IL6-A7.
Discussion
We used a ligase-mediated DNA-templated polymerization system and in vitro selection to evolve HFNAPs, nucleic acid polymers that are densely functionalized with chemically diverse side chains. HFNAPs that bind PCSK9 and IL-6 were selected from random polymer libraries. Through diversification and reselection, we evolved an improved PCSK9-binding HFNAP (Evo5) with a K D of 3 nM. We characterized the structure-activity relationships within this polymer to reveal side chains at specific positions that are critical to target-binding activity. Evo5 potently inhibits binding between PCSK9 and LDLR. TTT TTG TTC TGG CTA CGG CCT TTG CCC TTC CGG TAT CCC TCC TGT   TGT TGC TGG TTA CCG CCT CTC CTG TGG TGC TTC CGG CTG CGT TGT   TTG TGG TGT TGC TCT CAG TGC CGG TTA CCG TCG TGA CGC TTC CGA   TCA CCC CTT TGG CTG TGG TTG CAG TGC CCG TGG TCG CCT TAG CCA   TCC TGG TTA CGG CCT TTG TCG CCC TTC CCC CTC TCT CCC TCA TTG   TGC TGC TGT TTA TTT CGT TGC CCT TCC TCG TAC TCA TTC Collectively, these findings represent the laboratory evolution of functional, genetically encoded sequence-defined synthetic polymers without the constraints imposed by polymerases or ribosomes. The DNA-templated, ligase-based translation system developed here supports many rounds of iterated selection of polymers with diverse side chains, which include side chains that mimic-and extend beyond-the repertoire of amino acid side chains found in proteins. Both the PCSK9-binding and IL-6-binding polymers generated in this system exhibit position-dependent and side-chaindependent structure-activity relationships that resemble those of proteins. Finally, the PCSK9-binding polymers generated in this work are strongly dependent on the presence of multiple side chains with different physical properties, consistent with the importance of chemical diversity to the functional potential of these polymers.
Recently, Gawande and co-workers performed selections for PCSK9 aptamers from modified DNA libraries in which all instances of one or both pyrimidines (C and/or T) were replaced by side-chain-functionalized variants 27 . High-affinity aptamers with dissociation constants similar to those of FDA (Food and Drug Administration)-approved anti-PCSK9 monoclonal antibodies (evolocumab, K D = 8.0 pM (ref. 49 ), and alirocumab, K D = 0.58 nM (ref. 50 )) were enriched from doubly modified libraries in which hydrophobic or phenolic side chains were present on 50% of the nucleobases on average. Aptamers enriched from singly modified libraries (25% hydrophobic side chains on average) were less potent (K D ≥ 100 pM), whereas libraries that contained hydrophilic side chains or consisted of unmodified DNA did not produce aptamers with K D ≤ 30 nM. Consistent with their findings, the highest affinity binder from our HFNAP library, which contains a roughly equal mix of hydrophilic and hydrophobic side chains installed at 33% total frequency, has K D = 3 nM to PCSK9. However, different modifications may be suitable for other applications, as demonstrated by DNA-based catalysts functionalized with nitrogen nucleophiles as side chains [29] [30] [31] [32] [33] 35 . Therefore, the diverse and balanced set of side chains in HFNAPs, similar to the natural repertoire of proteins, may be more versatile in other settings.
The ligase-based polymerization method allows a straightforward redesign of the polymers' genetic code, as we exploited to expand the sequence and structural diversity of the polymers used in this work compared with those of our original system 39 . This feature also enables researchers to generate and select HFNAPs with side chains tailored towards specific applications, as recently demonstrated for scaffolding peptides on a DNA template 51 . Moreover, the side-chain flexibility of this polymer-evolution system raises the possibility of performing parallel evolution experiments with libraries of different side-chain compositions to shed light on the fundamental relationship between the structure of the building blocks in a genetic code and the evolutionary potential of the resulting polymers.
methods
Additional experimental procedures and characterization data are provided in the Supplementary Information.
Synthesis of HFNAP by templated translation via DNA ligase-mediated polymerization.
DNA template (up to 10 pmol, either in solution or immobilized on MyOne Streptavidin C1 magnetic beads (ThermoFisher Scientific)), polymerization initiation and termination primers (1.5 equiv. each relative to the template), functionalized trinucleotide building blocks (10 equiv. relative to the template for each occurrence of the corresponding codon) and 10 × T4 RNA ligase reaction buffer (1 μ l (New England Biolabs)) were mixed in a total volume of 8 μ l in a PCR tube. The mixture was subjected to the following temperature programme on a thermocycler: 95 °C for 10 s, 65 °C for 4 min, and a ramp from 65 °C to 4 °C at 0.1 °C every ten seconds. To the PCR tube were added 1 μ l of 10 mM adenosine triphosphate and 1 μ l of T3 DNA ligase (New England Biolabs). The reaction was incubated at 4 °C for 12 h and then at 16 °C for 2 h.
Selections of HFNAPs that bind protein targets. Selection bait was prepared by immobilizing recombinant protein onto AminoLink Plus aldehyde-functionalized agarose resin via reductive amination with a MicroLink Protein Coupling Kit (ThermoFisher Scientific). Loading was 1 mg of PCSK9 protein (ACROBiosystems) per millilitre of resin for the initial PCSK9 binder selection and the first two rounds of PCSK9 binder reselection, 150 μ g of PCSK9 per millilitre of resin for rounds 3-5 of the reselection, 40 μ g of protein per millilitre of resin for round 6 of the reselection and 250 μ g of IL-6 protein (PeproTech) per millilitre of resin throughout the IL-6 binder selection.
To initiate the selection, the primer extension was performed with a biotinylated primer on 5 pmol of the sense-strand randomized DNA library (Integrated DNA Technologies or TriLink BioTechnologies) with Klenow (exo-) polymerase (New England Biolabs). The biotinylated species was captured on streptavidin magnetic beads, which were then washed three times with 20 mM NaOH and then twice with 1 × T4 RNA ligase reaction buffer. The beadimmobilized template strand library was then translated in a ligase-mediated polymerization to produce HFNAPs. The beads were suspended in 20 mM NaOH to denature the HFNAP-template hybrids. HFNAP strands in the supernatant were cleaned up with a MinElute column (Qiagen).
The HFNAP library was added to Dulbecco's PBS (DPBS) (with calcium and magnesium (Lonza)) supplemented with BSA (0.1 mg ml -1 final) and Tween-20 (0.01% final), and then incubated with PCSK9 resin in a microspin filtration column (Pierce) at room temperature for 1 h on a rotor. (The amounts of resinbound protein used in each round of the PCSK9 selection are indicated in Fig. 2b . Throughout the IL-6 selection, 240 pmol of immobilized IL-6 protein were used in each round.) The flow-through was collected by centrifugation at 1,000g into an Eppendorf tube. The beads were washed three times with 50 μ l each of DPBS. The column was cut open, and the beads were collected by centrifugation into an Eppendorf tube and then incubated in 50 μ l of lithium dodecyl sulfate loading buffer (Life Technologies) at 95 °C for 15 min. After cooling, HFNAP strands were isolated from the mixture by cleaning up with a QiaQuick column (Qiagen), and the HFNAP eluted into 50 μ l of water.
Samples of 1 μ l each from the flow-through, the three washes and the elution were quantified by quantitative PCR (qPCR) (20 μ l reaction volume) using the iTaq Supermix (Bio-rad). The number of cycles for the qPCR curve of the elution sample to reach the end of exponential growth was used as the number of cycles for the preparative PCR (400 μ l of reaction volume split into eight 50 μ l portions) of the selected elution pool (20 μ l) with a Q5 Hot Start High-Fidelity 2X Master Mix (New England Biolabs), using a biotinylated primer for the strand that will serve as the translation template. The PCR product was cleaned up with a MinElute column and PAGE purified on a non-denaturing 10% TBE (tris/borate/EDTA) gel. A portion (indicated in Fig. 2b ) of the double-stranded DNA product was captured on streptavidin magnetic beads to initiate the next round of selection. SPR assays. All the SPR assays were performed at 25 °C on a Biacore X100 or Biacore T200 (GE Healthcare Life Sciences). Binding kinetics between the enzymatically synthesized biotinylated HFNAPs and unlabelled recombinant proteins were measured using single-cycle kinetics with the Biotin CAPture kit (GE Life Sciences) using 0.9 × HBS-EP buffer (GE Life Sciences) at a flow rate of 30 μ l min -1 . The injected PCSK9 concentration ranged from 10 to 300 nM for PCSK9-A5 and its variants, or from 2 to 60 nM for PCSK9-Evo5 and its variants. The injected IL-6 concentration ranged from 10 to 300 nM.
The binding kinetics between chemically synthesized PCSK9-Evo5-syn and biotinylated Avi-tagged PCSK9 (ACROBiosystems) were measured using singlecycle kinetics on a Series S SAchip (GE Life Sciences) using 0.9x HBS-EP buffer at a flow rate of 30 μ l min -1 . The injected PCSK9-Evo5-syn concentration ranged from 1.8 to 180 nM.
The binding of PCSK9 on surface-immobilized LDLR in the presence of various competing agents was measured on a Series S SA chip using 10 mM HEPES, 150 mM NaCl, 0.1 mM CaCl 2 , and 0.005% Tween-20, pH 7.5, as the bulk buffer at a flow rate of 10 μ l min -1 . The injected solutions contained 20 nM PCSK9 and various competing agents that ranged from 2 to 200 nM. Data availability. The principal data supporting the findings of this work are available within the figures and the Supplementary Information. Additional data that support the findings of this study are available from the authors on request.
